Author:
Fragulidis Georgios P.,Zafeirakis Athanasios G.,Limouris Georgios S.
Publisher
Springer International Publishing
Reference94 articles.
1. Lee SY, Cheow PC, Teo JY, et al. Surgical treatment of neuroendocrine liver metastases. Int J Hepatol. 2012;2012:146590. https://doi.org/10.1155/2012/146590.
2. Tao L, Xiu D, Sadula A, Ye C, et al. Oncotarget. 2017;8(45):79785–92.
3. Limouris GS, Dimitropoulos N, Kontogeorgakos D, et al. Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings. Cancer Biother Radiopharm. 2005;20:215–7.
4. Kontogeorgakos D. Dosimetry during therapeutic applications with octreotide labeled with In-111. ND 22105; 2006. http://hdl.handle.net/10442/hedi/22105.
5. Kontogeorgakos D, Dimitriou P, Limouris GS, et al. Patient-specific dosimetry calculations using mathematic models of different atomic sizes during therapy with In-111-DTPA-DPhe1 Octreotide infusions after catheterization of the hepatic artery. J Nucl Med. 2006;47(9):1476–82.